TG Therapeutics, Inc. (TGTX): Price and Financial Metrics

TG Therapeutics, Inc. (TGTX)

Today's Latest Price: $26.07 USD

0.93 (-3.44%)

Updated Oct 26 8:27pm

Add TGTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

TGTX Stock Summary

  • Tg Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.68% of US listed stocks.
  • Of note is the ratio of Tg Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 9.61% of US stocks have a lower such ratio.
  • With a price/sales ratio of 22,688.54, Tg Therapeutics Inc has a higher such ratio than 99.95% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Tg Therapeutics Inc, a group of peers worth examining would be NK, CYAD, TRVN, ATHX, and PSTI.
  • TGTX's SEC filings can be seen here. And to visit Tg Therapeutics Inc's official web site, go to

TGTX Stock Price Chart Interactive Chart >

Price chart for TGTX

TGTX Price/Volume Stats

Current price $26.07 52-week high $31.97
Prev. close $27.00 52-week low $5.90
Day low $25.37 Volume 1,978,700
Day high $27.00 Avg. volume 2,015,029
50-day MA $26.22 Dividend yield N/A
200-day MA $18.53 Market Cap 3.30B

TG Therapeutics, Inc. (TGTX) Company Bio

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.

TGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

TGTX Latest Social Stream

Loading social stream, please wait...

View Full TGTX Social Stream

Latest TGTX News From Around the Web

Below are the latest news stories about Tg Therapeutics Inc that investors may wish to consider to help them evaluate TGTX as an investment opportunity.

The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp ...

Benzinga | September 3, 2020

The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics...

Benzinga | September 2, 2020

FDA accepts TG Therapeutics' umbralisib application, action date February 2021

Under Priority Review status, the FDA accepts TG Therapeutics' ([[TGTX]] +4.9%) marketing application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma ((MZL)) who have received at least one prior anti-CD20 based regimen and follicular lymphoma ((FL)) who have received at least two prior systemic therapies.The...

Seeking Alpha | August 13, 2020

Why TG Therapeutics Is Trading Higher Today

TG Therapeutics (NASDAQ: TGTX ) shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients with the previously-treated marginal zone Lymphoma and … Full story available on

Benzinga | August 13, 2020

TG Therapeutics EPS misses by $0.13, revenue in-line

TG Therapeutics (TGTX): Q2 GAAP EPS of -$0.47 misses by $0.13.Revenue of $0.04M in-line (flat Y/Y).Press Release...

Seeking Alpha | August 10, 2020

Read More 'TGTX' Stories Here

TGTX Price Returns

1-mo 5.46%
3-mo 25.76%
6-mo 118.71%
1-year 351.04%
3-year 219.88%
5-year 93.40%
YTD 134.86%
2019 170.73%
2018 -50.00%
2017 76.34%
2016 -61.02%
2015 -24.68%

Continue Researching TGTX

Want to see what other sources are saying about Tg Therapeutics Inc's financials and stock price? Try the links below:

Tg Therapeutics Inc (TGTX) Stock Price | Nasdaq
Tg Therapeutics Inc (TGTX) Stock Quote, History and News - Yahoo Finance
Tg Therapeutics Inc (TGTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7406 seconds.